A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic dermatitis and psoriasis in a skin biopsy, according to a press release.
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.
Learn about different types of eczema, symptoms, treatment options, and how to differentiate from other skin conditions.
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Almirall has announced that it will be hosting the 16th edition of its Skin Academy, a conference that encourages ...
Journalist working with Al Jazeera killed in Israeli Gaza strike, network says Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16 th edition of Skin Academy, a ...
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...
Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...
A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...
IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.
Join Drs Steven Feldman and Robert Kushner as they discuss the role of dermatologists in treating obesity in conjunction with psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback